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We have analyzed the effectiveness of Hsp90 inhibitors in blocking the replication of negative-strand RNA viruses. In cells infected with the
prototype negative strand virus vesicular stomatitis virus (VSV), inhibiting Hsp90 activity reduced viral replication in cells infected at both high
and low multiplicities of infection. This inhibition was observed using two Hsp90 inhibitors geldanamycin and radicicol. Silencing of Hsp90
expression using siRNA also reduced viral replication. Hsp90 inhibition changed the half-life of newly synthesized L protein (the large subunit of
the VSV polymerase) from >1 h to less than 20 min without affecting the stability of other VSV proteins. Both the inhibition of viral replication
and the destabilization of the viral L protein were seen when either geldanamycin or radicicol was added to cells infected with paramyxoviruses
SV5, HPIV-2, HPIV-3, or SV41, or to cells infected with the La Crosse bunyavirus. Based on these results, we propose that Hsp90 is a host factor
that is important for the replication of many negative strand viruses.
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There is significant scientific and public health interest in
viruses that utilize negative strand RNA as genomes. Many of
these viruses are important pathogens, including some of the
most significant recurring infectious disease problems (influ-
enza, respiratory syncytial virus) as well as some of the most
alarming emerging infectious diseases (Lassa, Marburg, Hanta,
Rift Valley Fever). All of these viruses encode an RNA
dependent RNA polymerase (RDRP). The RDRP is required
both for viral transcription and for replication of the viral
genome (Whelan et al., 2004). In addition to RNA polymeriza-
tion, the RDRPs are also involved in 5′ and 3′ end modification
and in recognizing cis-acting sequences that govern transcrip-
tion and replication. Functionally, RDRPs from different viruses
appear to utilize diverse strategies to accomplish these tasks, but⁎ Corresponding author. Boston University, Department of Microbiology, 715
Albany Street, Boston, MA 02118-2526, USA. Fax: +1 617 638 4286.
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doi:10.1016/j.virol.2006.12.026a repeating theme is that the RDRP requires either cooperating
viral proteins (Gupta et al., 2003; Whelan et al., 2004) or host
proteins (Das et al., 1998; Shen and Masters, 2001; Strauss and
Strauss, 1999) to properly accomplish replication and/or
transcription. Understanding these virus/virus and virus/host
interactions that govern negative strand virus replication are
important for developing ways to combat important infectious
agents by blocking their ability to replicate.
Heat Shock Protein 90 (Hsp90) is a cellular chaperone that
has been the focus of intense research for many years (for
reviews see Terasawa et al., 2005; Young et al., 2001).
Knockout models have shown that Hsp90 is essential for
viability in yeast and Drosophila (Lange et al., 2000; Panaretou
et al., 1998; Rutherford and Lindquist, 1998). Hsp90 displays
ATP-dependent folding capacity (Panaretou et al., 1998), and is
notable among chaperone proteins because unlike its promis-
cuous cousin chaperone HSP70 (Agashe and Hartl, 2000),
Hsp90 appears to have a specific set of client proteins in vivo
(Pratt and Toft, 2003). These client proteins include steroid
receptors, a number of transcription factors, and several protein
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co-chaperones (i.e. AHA1, Hop/Sti1, FKBP51, and 52) which
then act to fold client proteins. Several known oncogenes are
client proteins of Hsp90 (Pratt and Toft, 2003), which has
sparked interest in using Hsp90 inhibitors to block the folding
of these oncogenic proteins in an effort to drive cancer cells into
apoptosis (Whitesell and Lindquist, 2005).
Hsp90 involvement in viral replication has been reported for
several different viruses; however, these reports have suggested
different roles of Hsp90 in a variety of virus and host systems.
During vaccinia virus infection, Hsp90 inhibition blocks viral
replication (Hung et al., 2002). The mechanism for this
inhibition is not well established, but Hsp90's localization is
restricted to the cytoplasm following VV infection, where it
interacts with the viral core protein 4a, presumably as a client
protein (Hung et al., 2002). Hsp90 activity has also been
reported to be important for proper cleavage of newly
synthesized hepatitis C NSP2/3 protein (Waxman et al.,
2001), and is required for the activity of the hepatitis B reverse
transcriptase (Hu and Seeger, 1996; Hu et al., 1997).
Recently, there have been several reports implicating a role
for Hsp90 in the control of viral polymerase function. In a
minireplicon system, Hsp90 binds to the PB2 subunit of the
influenza virus RNA polymerase, and stimulates viral poly-
merase activity (Momose et al., 2002). In Herpes virus
infection, blocking Hsp90 activity significantly inhibited viral
replication (Burch and Weller, 2005; Li et al., 2004), possibly
due to the improper localization of the viral polymerase in drug-
treated cells (cytoplasmic rather than nuclear). Similarly, it has
been shown that Hsp90 activity is important for the proper
stability and localization of the RNA polymerase (protein A) of
the insect virus flock house virus (Kampmueller and Miller,
2005).
There is still a great deal to be discovered about Hsp90's role
in virus replication, such as whether Hsp90 is likely to play a
role in the life cycle of specific viruses or whether it is involved
in the life cycle of entire classes of viruses. In an attempt to
address this question, we have studied the effects of Hsp90
inhibitors on the replication of several different prototype
negative strand RNA viruses from the rhabdovirus, paramyx-
ovirus, and bunyavirus families. We found that replication of
viruses from each of these families was impaired by the
ansamycin Hsp90 inhibitor geldanamycin, a second Hsp90
inhibitor radicicol, and by siRNA knockdown of Hsp90 protein
levels. This inhibition of replication was most apparent at early
stages of the virus life cycle and resulted in the selective
destabilization of the L protein of the virus polymerase. Based
on this and other data in the literature, we propose that viruses
frommultiple families and classes have all evolved to require the
use of Hsp90 for the proper folding of their polymerases. This
suggests that inhibitors of Hsp90 activity could act as broad-
range antiviral agents.
Results
To determine whether Hsp90 inhibition has an effect on the
replication of the prototype negative strand virus vesicularstomatitis virus (VSV), we determined viral growth in cells
treated with increasing concentrations of geldanamycin, an
ATP-competitor that acts as a specific inhibitor of Hsp90
activity (Roe et al., 1999). We utilized chemically synthesized
geldanamycin (provided by the DTP service of NCI) in these
experiments because a recent report has shown that geldana-
mycin purified from S. hygroscopicus contains contaminating
activities that inhibit intracellular trafficking but that the NCI
synthesized compound does not (Barzilay et al., 2004). BHK
cells infected with VSV at an MOI of 0.01 were treated with
increasing concentrations of drug, and virus yield at 12 hpi was
determined by plaque assay. As shown in Fig. 1A, geldanamy-
cin was a potent inhibitor of VSV growth, reducing virus
replication by 3 orders of magnitude at 100 nM and 5 orders of
magnitude at 5 μM.
To further understand the effect of geldanamycin on virus
replication, we carried out single and multiple cycle growth
experiments in the absence or presence of geldanamycin at
5 μM, a concentration previously shown to have minimal
cellular toxicity (Kampmueller and Miller, 2005). As shown in
Fig. 1B, geldanamycin had a significant effect on slowing virus
growth in a single cycle growth experiment (MOI=10). Cells
that were infected with VSV and treated with geldanamycin
showed a noticeable delay in virus growth, producing lower
virus titers between 4 and 16 hpi when compared to cells
infected with VSV but not treated with geldanamycin. By
24 hpi, virus titers were comparable between drug-treated and
untreated conditions. Inhibition of VSV replication by gel-
danamycin was seen in HeLa cells as well as in BHK cells
(data not shown), indicating that this effect was not cell-type
specific.
Inhibition of viral replication by geldanamycin was more
dramatic in multi-cycle growth experiments. Geldanamycin
addition delayed the appearance of progeny viruses for 8 h
when compared to infected cells that were not treated with
geldanamycin, and inhibited growth by more than two orders of
magnitude at 24 hpi (Fig. 1C). We also determined the effect of
radicicol, an Hsp90 inhibitor that is structurally distinct from
geldanamycin, on low MOI VSV infection. Radicicol also
inhibited VSV replication, decreasing virus titers by more than
2 orders of magnitude at 4 hpi and 4 orders of magnitude at
8 hpi. This supports the hypothesis that the mechanism of rep-
lication inhibition is through the inhibition of Hsp90 function
(Fig. 1D).
To test this conclusion utilizing a different method, we
determined the effect of decreasing the levels of Hsp90
through RNA silencing. Fig. 1E shows a representative
western blot of HeLa cells that were either mock transfected,
transfected with siRNA targeting GAPDH, or transfected with
siRNA targeting Hsp90. Forty-eight hours posttransfection,
cells transfected with GAPDH siRNA showed a >90%
inhibition of GAPDH expression (lane 2). Cells transfected
with siRNA targeting the alpha and beta forms of Hsp90
showed an 80–90% drop in Hsp90 levels at the same time
posttransfection (lanes 3–6). Cell cultures transfected with
either GAPDH or Hsp90 siRNA had fewer cells than controls
at 72 h posttransfection suggesting that cell proliferation was
Fig. 1. Effect of Hsp90 inhibition of VSV replication. (A) Viral titers at 12 hpi from cells infected with VSVat an MOI=0.01 and treated with increasing concentrations
of geldanamycin. (B) Growth curve of VSV in the presence (▵) or absence (▪) of geldanamycin (5 μM) at high MOI (=10) and (C) growth curve at low MOI (=0.1).
(D) Growth curve of VSV in the presence (▵) or absence (▪) of radicicol (5 μM). Virus titers for all panels represent the average of three different experiments. (E)
Western blot analysis of 25 μg of lysate from cells that were mock-transfected, transfected with GAPDH targeting siRNA, or transfected with Hsp90 targeting siRNA.
Top image shows Hsp90 levels, middle panel shows GAPDH levels, bottom panel shows actin as a loading control. (F) Growth curve of mock-transfected and siRNA-
treated cells infected with VSV at an MOI of 0.01. Error bars reflect standard deviation for three experiments.
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significant differences in cell viability or gross morphological
changes in cells transfected with Hsp90 siRNA. To determine
the effect of the lower levels of Hsp90 protein levels on VSV
infection, cells were infected with VSV at a low MOI (0.01).
Analysis of viral growth by plaque assay (Fig. 1F) showed
that cells where Hsp90 was silenced showed a decrease in
virus titer compared to a mock-transfected control at both 8
and 24 hpi, but that there was a negligible effect of GAPDH
silencing on virus titer. These results support the conclusionthat Hsp90 is an important host factor in the replication of
VSV.
Inhibition of virus replication is at early stages of viral
replication
The time-courses shown in Fig. 1 indicated that geldana-
mycin inhibited VSV at early times in the VSV life cycle, and
that the inhibitory action diminished at later times postinfection.
In a single-cycle growth experiment, drug added coincident
Fig. 3. Assembly of VSV in geldanamycin-treated cells. Cells were infected with
VSV for 5 h, and then proteins were radiolabeled and followed using a 1 h pulse
and 1 h chase protocol. Upon addition of radioactive methionine, different
concentrations of geldanamycin were added to individual samples. Following a
1 h chase in the presence of drug, (A) intracellular radiolabeling of protein was
determined by SDS-PAGE electrophoresis phosphorescence imaging. (B) The
amount of newly synthesized protein that was incorporated into the virus was
determined by virion purification from the media followed by SDS-PAGE and
phosphorescence analysis.
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added 4 h postinfection had almost no effect (data not shown).
This suggested that the antiviral activity of geldanamycin was
due to an effect on an early, rate-limiting step of viral
replication. To determine how the addition of geldanamycin
affected viral gene expression, cells were infected with VSVand
drug was added at 0, 2, or 4 hpi (see Fig. 2A for time line). At
5 hpi, cells were labeled with 35S methionine for 1 h and lysates
were analyzed by SDS-PAGE and phosphorimaging. In cells
that were not treated with drug, high level VSV gene expression
was evident through the appearance of four major bands
representing the L, G, N/P (comigrating), and M proteins (Fig.
2B, lane 1). Also apparent was the inhibition of host protein
synthesis normally seen following a productive VSV infection.
Addition of geldanamycin coincident with virus infection
blocked viral gene expression by VSV, but host protein
synthesis was still detectable (lane 2). Cells treated with drug
2 hpi showed some decrease in viral gene expression, and cells
treated with drug at 4 hpi showed strong viral gene expression,
demonstrating that geldanamycin inhibition of viral gene
expression required addition soon after initiating the infection.
As shown in Fig. 2B, the addition of drug at 4 hpi did result in
one change from non-treated cells: the viral L protein, the
catalytically active component of the RDRP accumulated to
much lower levels in these drug-treated cells.
Inhibition of stability of newly synthesized polymerase
To investigate whether the lower levels of L protein were
due to an increased incorporation of L into budded virions,
we determined the extent to which newly synthesized L was
incorporated into budding virions. At 4 hpi, infected cells
were treated with 50 nM, 500 nM, or 5 μM geldanamycin,
proteins were labeled with 35S methionine for 1 h and the fate
of the newly synthesized proteins was determined through
analysis of virions budded into the supernatant and labeled
protein in the cell after a 1 h chase with unlabeled
methionine. While most proteins produced by VSV were
unaffected by addition of geldanamycin, the level of L protein
in cell lysates decreased with increasing geldanamycinFig. 2. Effect of geldanamycin on viral protein synthesis. (A) Schematic of experimen
and total times of geldanamycin treatment (right). (B) Phosphorescence image of cell
described, followed by labeling with 35S methionine for 1 h.concentration (Fig. 3A). Drug addition at concentrations as
low as 50 nM decreased the amount of L in lysates,
consistent with the disappearance of the L protein being
linked to the effect of the drug on viral replication (Fig. 1A).
In budded virions purified from the supernatant of these same
cells, the concentration of geldanamycin did not have an
effect on the amounts of radiolabeled G, N, P, and M protein
that were incorporated (Fig. 3B), demonstrating that blocking
Hsp90 does not affect any of the assembly function of the
virus. In the case of the L protein, less radiolabeled L protein
was incorporated into virions as geldanamycin concentration
increased. This result shows that geldanamycin treatment did
not result in the preferential movement of newly synthesized
L protein into virions. Some newly synthesized L was found
in virions from cells treated with lower concentrations of
drug, indicating that some of the newly synthesized L protein
remains in the cell long enough to be incorporated into
virions.tal procedure showing times of geldanamycin treatment after viral infection (top)
lysates from cells that were infected with VSVand treated with geldanamycin as
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changed following Hsp90 inhibition, we performed pulse-chase
analysis in the presence and absence of geldanamycin.
Radiolabeled cells were chased for 10, 20, or 30 min, and
then lysates from these cells were analyzed by phosphorimaging
(Fig. 4A). The resulting image showed that in both geldana-
mycin-treated and untreated cells infected with virus significant
amounts of 35S methionine were incorporated into the viral L
protein. The newly synthesized L protein was stable in untreated
cells but disappeared rapidly in cells treated with the drug and
was almost completely absent after a 30 min chase. Quantitation
of these data (Fig. 4B) over multiple experiments showed that
the half-life of the L protein was greater than 60 min in the
absence of drug but was reduced to less than 20 min in the
presence of drug. This was not seen for the other viral proteins
as analysis of the decay of viral M protein (Fig. 4C) and the
other viral proteins (Fig. 4A) showed little evidence of
degradation in the presence and absence of drug treatment.
L protein is degraded by the proteasome
To investigate a possible mechanism for the observed
destabilization of L protein following HSP90 inhibition, we
determined whether the L protein was being degraded via the
proteasome. This possibility is particularly plausible because
other Hsp90 substrates, such as the estrogen receptor, have been
shown to be shunted to the proteasome pathway following
Hsp90 inhibition (Bagatell et al., 2001; Fan et al., 2005). To test
whether the proteasome is involved in the degradation of newly
synthesized L protein, we repeated the experiments shown in
Fig. 4, but added proteasome inhibitor (proteasome inhibitor II,
Calbiochem) to infected cells treated with geldanamycin. At
10 min of chase, there were similar levels of incorporation of
35S methionine into L protein in untreated, geldanamycin-
treated, and geldanamycin+proteasome inhibitor-treated con-
ditions (Fig. 5A). At 30 min chase, there was a significant
decrease in the amount of L protein in the geldanamycin-treated
cells similar to that seen in previous experiments. There was aFig. 4. Effect of geldanamycin on viral protein stability. (A) BHK cells infected with V
were determined by pulse-chase analysis (see Materials and methods). Results wer
identified to the right of the gel. Levels of protein remaining are quantities for viral
Values represent the average of three separate experiments ± standard deviation.much smaller decrease in the cells treated with both
geldanamycin and proteasome inhibitor showing that protea-
some inhibition decreased the degradation of the L protein.
Addition of proteosome inhibitor alone did not significantly
alter the stability of the L protein (Fig. 5B). The quantitation of
multiple experiments (Fig. 5C) showed that the addition of the
proteasome inhibitor increased L protein half-life in the
presence of geldanamycin from less than 20 min to close to
that of L in control cells that did not receive geldanamycin
(dotted line, Fig. 5B). This argues that the primary cause of the
disappearance of the newly synthesized L polymerase following
Hsp90 inhibition is the targeting of the newly synthesized
polymerase to the proteasome for degradation.
Hsp90 inhibitors regulate the replication and stability of
multiple negative strand viruses
Based on our findings that Hsp90 inhibitors decreased the
replication and destabilized the L polymerase protein of the
prototype negative strand virus VSV, we were interested in
whether this behavior was unique to VSV or whether it was a
more general phenomenon. To test the hypothesis that Hsp90
activity is required for replication and polymerase stability
across negative strand virus families, we initially tested the
paramyxoviruses simian virus 5 (SV5) and HPIV-2. To
determine the effect of Hsp90 inhibition on viral replication,
geldanamycin was added to cells that were infected at a low
multiplicity with a GFP-expressing SV5 (rSV5-GFP) or HPIV-
2. As shown in Fig. 6A, geldanamycin inhibited the growth of
these viruses, reducing virus yield by more than 3 logs for SV5
and more than 2 logs for HPIV2.
Both geldanamycin and radicicol blocked paramyxovirus
spread in a low MOI infection. Cells infected at an MOI of 0.05
with were all infected with rSV5-GFP and expressing GFP by
72 hpi (Fig. 6B left panels). Consistent with the effect of HSP90
inhibitors on virus production, cells infected with rSV5-GFP
but treated with 0.5 μM geldanamycin showed dramatically
lowered viral spread, with only a few cells showing GFPSV for 5 h were starved for methionine, and then protein synthesis and stability
e determined by SDS-PAGE and phosphorescence imaging. Viral proteins are
L (B) and M (C) proteins presence (▵) or absence (▪) of 5 μM geldanamycin.
Fig. 6. Effect of geldanamycin on paramyxovirus growth and L stability. (A and B) Cells were infected at an MOI of 0.05 with rSV5-GFP or HPIV-2 and
incubated with or without 0.5 μM geldanamycin. At 72 hpi, virus titers were determined by plaque assay (A) or cells were examined for GFP expression (B).
Results are representative of three independent experiments. (C and D) Cells that were mock-transfected or transfected with either GAPDH targeting siRNA or
Hsp90 targeting siRNA were infected with SV5-GFP at an MOI of 0.05. (C) Shows SV5-GFP growth curve (done in triplicate) untransfected (▪), GAPDH
siRNA transfected (♦), and Hsp90 siRNA transfected (▪); (D) shows representative images showing cell spread of the virus in different transfection
conditions.
Fig. 5. Geldanamycin destabilization of VSV L protein requires proteosome function. (A) BHK cells were infected with VSV, and 5 hpi left untreated, treated
with geldanamycin, or treated with both geldanamycin and proteosome inhibitor. Pulse-chase results for 10 min and 30 min chases are shown. (B) Stability of L
protein in the proteins presence (▵) or absence (▪) of 5 μM geldanamycin and in the presence of geldanamycin and a proteosome inhibitor (♦, dotted line).
Levels are expressed as a percentage of the signal that was present at the 10 min chase. Values are the average of three separate experiments ± standard
deviation.
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Fig. 7. Hsp90 inhibition destabilizes newly synthesized L proteins from multiple paramyxoviruses. (A) Cells were mock infected (M lane) or infected at an MOI of 10
with rSV5-GFP. At 13 hpi, cells were treated for 1 h with or without 1 μM Geldanamycin. Cells were radiolabeled for 20 min with 35S-amino acids and incubated in
nonradioactive media for the indicated times before lysis and analysis by immunoprecipitation with antibodies specific for NP, P, or L. Geldanamycin was included at
1 μMduring radiolabeling and chase periods. (B) Stability of L proteins. Cells were mock infected or infected at an MOI of 10 with SV5, HPIV-2, SV41, or HPIV-3. 13
hpi, cells were treated with 1 μM geldanamycin, radiolabeled for 20 min and lysed (Pulse) or chased using unlabeled methionine for 1 h (Chase). Following cell lysis,
samples were immunoprecipitated using L-specific antibodies. (C) Experiments similar to B were carried out, but 1 μM radicicol was used instead of geldanamycin.
115J.H. Connor et al. / Virology 362 (2007) 109–119expression (middle panels). A similar limitation of spread was
seen in cells treated with radicicol, with few cells showing the
intense GFP signal seen in mock-infected cells (right panels).
Using siRNA to decrease the level of Hsp90 protein in
cells also had a significant effect on paramyxovirus replica-
tion. Shown in Fig. 6C are SV5-GFP virus titers at 24, 48,
and 72 hpi from HeLa cells that were either mock transfected,
transfected with siRNA targeting GAPDH, or transfected withFig. 8. Geldanamycin inhibition of La Crosse virus replication. (A) La Crosse virus tit
geldanamycin at time of infection. (B) Light microscope images of cells infected with
Protein synthesis and stability of La Crosse L and G1 proteins. 16 hpi with Lacrosse v
lysed (P) or incubated in non-radioactive media for 1 h. Cells were then lysed, and i
followed by phosphorescence imaging.siRNA targeting Hsp90. Silencing GAPDH minimally
decreased the replication of SV5-GFP, but silencing Hsp90
reduced SV5-GFP replication significantly. Progeny viruses
were not detected at 24 hpi in Hsp90-silenced cells infected
with SV5-GFP, a 3 log order difference compared to control
and GAPDH-silenced cells. Virus replication was observed at
both 48 and 72 hpi, but at lower levels than was seen in
controls. Silencing of Hsp90 expression but not silencing ofers at 24 hpi from cells infected at an MOI=0.01 and increasing concentrations of
La Crosse virus in the absence (left) and presence of 0.5 μM geldanamycin. (C)
irus at an MOI of 1, cells were labeled with 35S-methionine for 20 min and then
ncorporation of radioactivity into viral proteins was determined by SDS-PAGE
116 J.H. Connor et al. / Virology 362 (2007) 109–119GAPDH expression inhibited the spread of SV5 GFP (Fig.
6D) in these cells.
This inhibition of paramyxovirus growth was accompanied
by changes in the stability of the viral polymerase. Fig. 7A
shows the results of pulse-chase (0.5, 1 and 2 h chase, followed
by immunoprecipitation of indicated protein) experiments that
were used to follow the stability of individual SV5 viral
proteins. In cells infected with rSV5-GFP but not treated with
geldanamycin, L, N and P proteins showed very stable profiles,
with the polymerase protein L showing a half-life in excess of
1 h. In geldanamycin-treated cells infected with SV5-GFP, both
the N and P proteins remained stable, but the half-life of the L
protein dropped to less than half an hour following treatment
with geldanamycin, similar to the polymerase destabilization
observed in the case of the VSV polymerase.
In addition to showing antiviral activity against SV5 and
HPIV-2, both geldanamycin and radicicol showed antiviral
activity against SV41 and HPIV3 (data not shown). Analysis of
the viral polymerase of each of these viruses (Fig. 7B) directly
following pulse labeling (P) for 20 min or after a 1 h chase (C)
showed that (1) all of these polymerase proteins were stable in
the absence of geldanamycin, and (2) all displayed a marked
decrease in the half-life of the L polymerase protein following
geldanamycin addition. (3) The amount of labeled L protein
following the 20 min pulse was reduced in the presence of
geldanamycin, suggesting that turnover was occurring during
the pulse period. The stability of SV41 L protein appeared to be
most significantly decreased in the presence of geldanamycin,
suggesting a very rapid turnover of the L protein in this virus
following HSP90 treatment. These effects of destabilization of
these viral L proteins were attributable to Hsp90 inhibition, as
treatment of cells infected with SV5, SV41 or HPIV-3 with
radicicol also caused the rapid degradation of newly synthesized
viral polymerase (Fig. 7C).
HSP90 inhibitors block the replication of La Crosse virus
We also tested the impact of Hsp90 inhibition on the
replication of Bunyaviruses, a family of negative-strand viruses
containing segmented RNA genomes. In the case of the pediatric
encephalitis virus, La Crosse virus (H78 strain (Chandler et al.,
1998), a kind gift from B.J. Beaty), virus growth was also
inhibited by geldanamycin (Fig. 8A) and radicicol (data not
shown) at concentrations as low as 100 nM. In cells not treated
with drug, La Crosse virus infection resulted in the development
of noticeable cytopathic effects (Fig. 8B, left panel). Infection
with La Crosse in the presence of geldanamycin prevented the
development of cytopathic effect (Fig. 8B, right panel),
consistent with the observed inhibition of virus replication.
Similar to VSV and paramyxovirus family members, HSP90
inhibition appeared to destabilize the viral polymerase. Pulse-
chase analysis of La Crosse virus proteins in infected cells
(30 min pulse followed by a 1 h chase) showed that La Crosse L
protein is normally stable, but there was a distinct decrease in L
protein stability following the addition of geldanamycin (Fig.
8C, top panel), while other La Crosse virus proteins such as the
glycoprotein G1 remained stable (bottom panel).Discussion
The experiments described here demonstrate through both
gene-knockdown and cell-permeable inhibitor approaches that
Hsp90 activity is important for the rapid growth of negative
strand RNA viruses. Mechanistically, geldanamycin and other
Hsp90 inhibitors appear to block virus replication by dramati-
cally decreasing the stability of the L subunit of the viral RNA
dependent RNA polymerase. This mode of action would explain
the effectiveness of Hsp90 inhibition at early stages of viral
infection where the level of RNA synthesis and genome
replication would be most affected by decreased levels of the
viral polymerase. Adding geldanamycin at progressively later
times postinfection has progressively less effect on viral gene
expression, indicating that accumulation of L protein prior to
drug addition can compensate for the rapid turnover of newly
synthesized L protein. Our studies show that viruses from the
rhabdovirus, paramyxovirus, and bunyavirus families all require
Hsp90 activity to achieve normal levels of a stable viral
polymerase. Other researchers have shown that the positive-
strand RNA virus FHV polymerase (Kampmueller and Miller,
2005) and the influenza virus polymerase (Momose et al., 2002)
require Hsp90 activity for proper function. Together, our data
and that from other laboratories (Kampmueller andMiller, 2005;
Momose et al., 2002) suggest that Hsp90 is a host factor that is of
central importance to viral replication for many, if not all, RNA
viruses. The RNA polymerases from these different viruses do
not share a high degree of sequence homology, so their
dependence on Hsp90 points to convergent evolution. To our
knowledge, we are the first to propose that Hsp90 activity is a
conserved requirement for achieving a stable virus polymerase
for a wide spectrum of RNA viruses.
For the VSV L protein, its large size (241 kDa) and the
existence of several different catalytic activities within the
protein (Feller et al., 2000; Grdzelishvili et al., 2006; Li et al.,
2005, 2006) imply a number of independently folded domains.
This is also likely true of the other viral polymerases affected by
Hsp90 inhibition, as the viruses used in this study all have
relatively large polymerase proteins (∼240 kDa) that are likely
to have independent functional domains. How Hsp90 is
involved in folding these polymerases has yet to be determined,
but because Hsp90's protein folding activity requires the
binding and action of additional co-chaperones, the folding of
viral polymerases is likely to be a coordinated effort of several
cellular proteins, of which Hsp90 is the first to be identified.
Despite the attractiveness of hypothesizing that Hsp90 is
directly involved in folding viral polymerases, other possibi-
lities exist for how Hsp90 inhibition might destabilize RNA
virus polymerases. For viruses of the rhabdovirus and
paramyxovirus families, the L polymerase requires the binding
of the viral phospho (P) protein for activity (Horikami et al.,
1992). Hsp90 may facilitate the L–P interaction to promote the
stability of L. Hsp90 could also act to promote the stable
formation of L protein multimers (Smallwood et al., 2002).
Thus, Hsp90 inhibition could lead to a disruption of L–L
interactions resulting in an unstable polymerase that is quickly
degraded. Additionally, Hsp90 may be more remotely involved
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component that is required for polymerase stability. Further
experiments will be required to determine the interaction
between Hsp90 and RNA virus polymerases, as well as other
cellular factors.
The importance of Hsp90 for the replication of multiple
viruses opens an interesting possibility for developing new
antiviral therapies. There are few compounds that display
antiviral activity against major encephalitis-causing and hemor-
rhagic fever-causing negative strand RNA viruses (De Clercq,
2005; Domachowske and Rosenberg, 2005). Our findings
suggest that the inhibition of Hsp90 activity should be
investigated as a mechanism of limiting the replication and
spread of these viruses in vivo. An advantage of this approach is
that the lack of Hsp90 activity appears to hamper viral RDRP
function. The RDRP represents a rate limiting enzyme step in
virus replication that performs many unique and essential
replication functions and is synthesized at relatively low levels
in infected cells. Additionally, because of the effectiveness of
this compound against a wide variety of viruses, Hsp90
inhibitors may be broad spectrum antivirals capable of
inhibiting the replication of several different infectious agents.
Already, significant effort has been devoted to developing
Hsp90 inhibitors. One of these compounds, 17-AAG (a
geldanamycin derivative) has completed phase 1 and is currently
in phase 2 clinical trials as an anticancer therapy (Goetz et al.,
2005; Whitesell and Lindquist, 2005). Results from phase 1
trials showed that tolerated doses of the drug led to decreases in
the levels of Hsp90 client proteins (Banerji et al., 2005; Grem et
al., 2005). Thus, this compound has already passed many of the
hurdles that confront successful drug development, and it or
other Hsp90 inhibitors in development (Whitesell and Lindquist,
2005) are likely to be clinically viable. Regardless of their utility
in cancer treatment, we propose that further experimentation
should be undertaken to determine whether these compounds
have a useful role as antiviral agents. Hsp90 inhibitors may also
work synergistically with other antivirals such as ribavirin, a
drug that has also been suggested to target the function of the
viral polymerase (Graci and Cameron, 2002).
An important corollary to these findings is that these
studies highlight the utility of prototype negative strand
viruses as tools that can be used to screen for new antiviral
compounds. Utilization of viruses that have shown minimal
human pathogenicity and have been well characterized offers
significant advantages over newly discovered or highly
pathogenic viruses for lead compound identification and can
serve as an important stepping stone to the discovery of new
antiviral compounds that have a wide spectrum of antiviral
activities.
Materials and methods
Reagents
Geldanamycin was synthesized at the drug therapeutics
program of the NIH. Radicicol and proteosome inhibitor II
were obtained from Calbiochem. 35S Methionine wasobtained from Amersham. siRNA targeting Hsp90 and
polyclonal anti-Hsp90 antibody were obtained from Santa
Cruz. siRNA transfection reagent was obtained from Mirus
biotechnology. siRNA targeting GAPDH was obtained from
Dharmacon, antibody recognizing GAPDH was obtained from
chemicon. All other reagents were obtained from Fischer Co.
La Crosse virus (H78) was a kind gift of Barry Beaty
(Colorado State University).
Virus infection
Cells were plated to reach a density of between 70 and 80%
in DMEM+10%FBS. Cells were infected with VSV at an
MOI=10 or an MOI=0.01 as described previously (Connor and
Lyles, 2002). For dose–response experiments with VSVand La
Crosse virus, BHK cells were infected at an MOI of 0.01 and
virus budded into culture media was determined by plaque
assay using BHK cells. Drugs were added coincident with
infection unless otherwise indicated.
siRNA knockdown experiments
For siRNA targeting the human alpha and beta forms of
Hsp90, HeLa cells were incubated with 50 nM siRNA using
Mirus siPORT transfection reagent for 48 h prior to infection
with VSV. For GAPDH siRNA, 75 nM siRNA was utilized
using the same transfection reagent. For both Hsp90 and
GAPDH siRNA transfections, there was no obvious cytotoxi-
city at 48 h posttransfection.
Pulse-chase experiments
For VSV, cells were infected with VSV for 5 h. Cells were
labeled with 35S methionine-containing media for 1 h and then
the radioactive media was replaced with media containing
unlabeled methionine for an hour or for the times indicated in
text describing the figure. For La Crosse virus, a similar
procedure was followed, but cells were labeled 16 hpi for
30 min and chased for 60 min. Cells were lysed in RIPA buffer
and proteins were separated by SDS-PAGE. For virion
purification, media from infected cells were layered on top
of a 15% sucrose solution and spun for some 40,000×g for
45 min. Pelleted virions were resuspended and proteins were
separated by SDS-PAGE.
Paramyxovirus experiments
Infections of HeLa cells at high MOI (10) or low MOI (0.05)
with SV5 expressing GFP (rSV5-GFP), HPIV-2, HPIV-3, or
SV41 and virus growth analyses were carried out as described
previously (Parks et al., 2001). Geldanamycin or radicicol was
added after attachment of virus to cells, and was maintained
throughout growth experiments. GFP expressing cells were
analyzedwith theNikonEclipsemicroscope and a 20× objective.
Images were captured using a QImaging digital camera and
processed using QCapture software. Exposure times were
manually set to be constant between samples. For radiolabeling
118 J.H. Connor et al. / Virology 362 (2007) 109–119experiments, cells were treated with Geldanamycin for 1 h prior
to radiolabeling with Tran35S-label (100 uCi/ml), lysed in SDS,
and used for immunoprecipitation analysis with polyclonal
antibodies specific for the SV5 NP, P, or L proteins as described
previously (Parks et al., 2001).
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